Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial.
Friedman-Klabanoff DJ, Birkhold M, Short MT, Wilson TR, Meneses CR, Lacsina JR, Oliveira F, Kamhawi S, Valenzuela JG, Hunsberger S, Mateja A, Stoloff G, Pleguezuelos O, Memoli MJ, Laurens MB.
Friedman-Klabanoff DJ, et al. Among authors: memoli mj.
EBioMedicine. 2022 Dec;86:104375. doi: 10.1016/j.ebiom.2022.104375. Epub 2022 Nov 24.
EBioMedicine. 2022.
PMID: 36436281
Free PMC article.
Clinical Trial.